181 related articles for article (PubMed ID: 18262053)
1. Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders.
Gallagher G; Horsman DE; Tsang P; Forrest DL
Cancer Genet Cytogenet; 2008 Feb; 181(1):46-51. PubMed ID: 18262053
[TBL] [Abstract][Full Text] [Related]
2. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
[TBL] [Abstract][Full Text] [Related]
3. KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).
Levine RL; Wadleigh M; Sternberg DW; Wlodarska I; Galinsky I; Stone RM; DeAngelo DJ; Gilliland DG; Cools J
Leukemia; 2005 Jan; 19(1):27-30. PubMed ID: 15496975
[TBL] [Abstract][Full Text] [Related]
4. Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms.
Hidalgo-Curtis C; Apperley JF; Stark A; Jeng M; Gotlib J; Chase A; Cross NC; Grand FH
Br J Haematol; 2010 Jan; 148(2):268-73. PubMed ID: 20085582
[TBL] [Abstract][Full Text] [Related]
5. Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2).
Walz C; Haferlach C; Hänel A; Metzgeroth G; Erben P; Gosenca D; Hochhaus A; Cross NC; Reiter A
Genes Chromosomes Cancer; 2009 Feb; 48(2):179-83. PubMed ID: 19006078
[TBL] [Abstract][Full Text] [Related]
6. KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia.
Medves S; Duhoux FP; Ferrant A; Toffalini F; Ameye G; Libouton JM; Poirel HA; Demoulin JB
Leukemia; 2010 May; 24(5):1052-5. PubMed ID: 20164854
[No Abstract] [Full Text] [Related]
7. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.
Walz C; Metzgeroth G; Haferlach C; Schmitt-Graeff A; Fabarius A; Hagen V; Prümmer O; Rauh S; Hehlmann R; Hochhaus A; Cross NC; Reiter A
Haematologica; 2007 Feb; 92(2):163-9. PubMed ID: 17296564
[TBL] [Abstract][Full Text] [Related]
8. Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.
Gosenca D; Kellert B; Metzgeroth G; Haferlach C; Fabarius A; Schwaab J; Kneba M; Scheid C; Töpelt K; Erben P; Haferlach T; Cross NC; Hofmann WK; Seifarth W; Reiter A
Genes Chromosomes Cancer; 2014 May; 53(5):411-21. PubMed ID: 24772479
[TBL] [Abstract][Full Text] [Related]
9. NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder.
Vizmanos JL; Novo FJ; Román JP; Baxter EJ; Lahortiga I; Larráyoz MJ; Odero MD; Giraldo P; Calasanz MJ; Cross NC
Cancer Res; 2004 Apr; 64(8):2673-6. PubMed ID: 15087377
[TBL] [Abstract][Full Text] [Related]
10. Philadelphia chromosome-negative myeloproliferative neoplasm with a novel platelet-derived growth factor receptor-β rearrangement responsive to imatinib.
Cornfield D; Shah U; Cross N; Bennett C; Sun G
J Clin Oncol; 2012 Mar; 30(9):e109-11. PubMed ID: 22331939
[No Abstract] [Full Text] [Related]
11. Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders.
Baxter EJ; Kulkarni S; Vizmanos JL; Jaju R; Martinelli G; Testoni N; Hughes G; Salamanchuk Z; Calasanz MJ; Lahortiga I; Pocock CF; Dang R; Fidler C; Wainscoat JS; Boultwood J; Cross NC
Br J Haematol; 2003 Jan; 120(2):251-6. PubMed ID: 12542482
[TBL] [Abstract][Full Text] [Related]
12. Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement.
Arefi M; García JL; Peñarrubia MJ; Queizán JA; Hermosín L; López-Corral L; Megido M; Giraldo P; de las Heras N; Vanegas RJ; Gutiérrez NC; Hernández-Rivas JM
Eur J Haematol; 2012 Jul; 89(1):37-41. PubMed ID: 22587685
[TBL] [Abstract][Full Text] [Related]
13. Congenital and childhood myeloproliferative disorders with eosinophilia responsive to imatinib.
Abraham S; Salama M; Hancock J; Jacobsen J; Fluchel M
Pediatr Blood Cancer; 2012 Nov; 59(5):928-9. PubMed ID: 22488677
[TBL] [Abstract][Full Text] [Related]
14. Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms.
Naumann N; Schwaab J; Metzgeroth G; Jawhar M; Haferlach C; Göhring G; Schlegelberger B; Dietz CT; Schnittger S; Lotfi S; Gärtner M; Dang TA; Hofmann WK; Cross NC; Reiter A; Fabarius A
Genes Chromosomes Cancer; 2015 Dec; 54(12):762-70. PubMed ID: 26355392
[TBL] [Abstract][Full Text] [Related]
15. Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13), PDGFRB-NDE1 fusion.
Cavazzini F; Bardi A; Ciccone M; Rigolin GM; Gorello P; La Starza R; Mecucci C; Cuneo A
Cancer Genet Cytogenet; 2009 Oct; 194(1):67-9. PubMed ID: 19737658
[No Abstract] [Full Text] [Related]
16. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders.
Cross NC; Reiter A
Acta Haematol; 2008; 119(4):199-206. PubMed ID: 18566537
[TBL] [Abstract][Full Text] [Related]
17. Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: a new case report.
Pitini V; Arrigo C; Teti D; Barresi G; Righi M; Alo G
Haematologica; 2003 May; 88(5):ECR18. PubMed ID: 12745287
[TBL] [Abstract][Full Text] [Related]
18. Molecular diagnosis and targeted therapy of a pediatric chronic eosinophilic leukemia patient carrying TPM3-PDGFRB fusion.
Li Z; Yang R; Zhao J; Yuan R; Lu Q; Li Q; Tse W
Pediatr Blood Cancer; 2011 Mar; 56(3):463-6. PubMed ID: 21072821
[TBL] [Abstract][Full Text] [Related]
19. Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib.
Wilkinson K; Velloso ER; Lopes LF; Lee C; Aster JC; Shipp MA; Aguiar RC
Blood; 2003 Dec; 102(12):4187-90. PubMed ID: 12907457
[TBL] [Abstract][Full Text] [Related]
20. Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia.
Winkelmann N; Hidalgo-Curtis C; Waghorn K; Score J; Dickinson H; Jack A; Ali S; Cross NC
Leuk Lymphoma; 2013 Jul; 54(7):1527-31. PubMed ID: 23186533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
